AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ----
“With an increasing number of gene therapies moving toward approval, manufacturing continues to be a critical component of success with respect to safety, regulatory approval and commercial viability,” said
“Engagement with patients and caregivers is a critical success factor in enhancing our understanding of retinal disorders, guiding clinical trial design, and inspiring our patient-centric culture,” said
To learn more about the event and registration, please visit: https://genetherapy-conference.com/.
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.
Chief Financial Officer
T: (617) 843-5728
Chief Business Officer
T: (617) 413-2754
Source: Applied Genetic Technologies Corporation